Compound ID | 1239
FG-LpxC-LUNG
Class: Lipopolysaccharide synthesis inhibitor (LpxC inhibitor)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Serious lung infections attributed to Gram-negative bacteria including multi-drug resistant P. aeruginosa |
| Institute where first reported: | Entasis Therapeutics |
| Highest developmental phase: | Preclinical |
| Development status: | Active |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.